

Cite this: *RSC Adv.*, 2017, 7, 7382

Facile synthesis of biocompatible MoSe₂ nanoparticles for efficient targeted photothermal therapy of human lung cancer†

Chunlei Zhong,* Xin Zhao, Lijiang Wang, Yunxia Li and Yingying Zhao

Two-dimensional molybdenum selenide (MoSe₂) nanosheets have been explored for their use as photothermal agents in tumor therapy although several biocompatibility and stability issues have hindered their use. Herein, a facile strategy to prepare PLGA–MoSe₂ mixture coated with a folate (FA)-modified PEG-lipid shell led to the synthesis of multifunctional nanoparticles (FA–PL–MoSe₂). The PEG-lipid shells endowed the insoluble MoSe₂ nanosheets with excellent colloidal stability. FA–PL–MoSe₂ nanoparticles did not only exhibit good photothermal properties, but also excellent photothermal stability. The FA conjugation promoted a high nanoparticle specificity to target human lung cancer SPC-A-1 cells as well as tumor tissue. *In vitro* cellular experiments demonstrated that FA–PL–MoSe₂ had minor cytotoxicity, great biocompatibility, and could efficiently kill tumor cells under near-infrared laser (NIR, 808 nm) irradiation. Following about 1 month of treatment, FA–PL–MoSe₂ showed good hemo-/histocompatibility combined with NIR irradiation and an improved tumor inhibition effect compared to PL–MoSe₂, with no relapse and no significant systemic *in vivo* toxicity.

Received 26th November 2016

Accepted 14th January 2017

DOI: 10.1039/c6ra27384j

www.rsc.org/advances

Introduction

Lung cancer incidence is increasing worldwide, resulting in millions of deaths annually.^{1,2} Currently, common treatments of lung cancer include surgical resection,³ radiofrequency ablation,⁴ and chemotherapy.⁵ However, these therapeutic strategies have detrimental side effects such as surgical wounds, compromised cardiopulmonary function, medical comorbidities,⁶ pneumothorax,^{7,8} and multidrug resistance,^{9,10} among others. Thus, these shortcomings require the development of alternative minimally invasive treatments. In recent years, photothermal therapy combined with NIR laser irradiation has been reported as a minimally invasive cancer treatment, attracting great research interest.^{11–14} Highly efficient photothermal therapy needs excellent photothermal agents able to absorb the NIR laser and converting it into hyperthermia to destroy tumor cells.^{15,16}

To date, two-dimensional (2D) layered transition metal dichalcogenides have drawn great attention as photothermal agents for photothermal therapy due to their novel electronic and optical properties.^{17,18} They are generally prepared with the formula MX₂ (M, transition metal atoms; X, chalcogen atoms), and include MoS₂, WS₂, TiS₂, among others.^{19–22} The exfoliated transition-metal dichalcogenides (MoS₂, WS₂, and WSe₂) have

been reported to have lower cytotoxicity than those of classic 2D materials such as graphene and its analogues.²³ Among transition metal dichalcogenide materials, molybdenum selenide (MoSe₂) nanosheets possess an obvious NIR absorption peak, indicating their great potential as NIR photothermal transducers.^{24–26} However, their poor dispersibility in water and lack of active specificity hinder its bioapplication in tumor photothermal therapy. Further processing techniques, such as ultrasonication to produce MoSe₂ nanodots and poly(vinylpyrrolidone) modification, have been reported to lead to the formation of biocompatible nanosheets.^{24–26} Therefore, the advent of more facile processing strategies and assembly techniques for MoSe₂ nanosheets formation with excellent biocompatibility and multifunctionality is urgently required.

Herein, a facile self-assembly method based on PLGA and PEG-lipid was used to prepare biocompatible MoSe₂ nanoparticles (FA–PL–MoSe₂, Fig. 1) consisting of a PLGA/MoSe₂ core and a PEG-lipid shell. The PEG-lipid coating endows these nanosheets with excellent hydrophilicity. Since tumor targeting is a promising strategy to better exploit the potential of photothermal agents in photothermal therapy, in order to enhance the tumor therapeutic effect, folate (FA), a water-soluble vitamin essential for human health, was conjugated onto the shells to target the FA receptors overexpressed in lung cancer cells.^{27–29} The toxicity and biocompatibility of FA–PL–MoSe₂ were systematically evaluated *in vitro* and *in vivo* and lung cancer cells and tumor tissues were treated with FA–PL–MoSe₂ under 808 nm laser irradiation in order to confirm the photothermal therapy effect.

The Second Department of Respiratory Medicine, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China. E-mail: zhongclei@163.com

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra27384j






Fig. 1 A schematic illustration of FA-PL-MoSe₂ nanoparticles preparation and tumor targeted photothermal therapy.

Experimental section

Materials

Bulk MoSe₂ powder was purchased from Alfa Aesar Co. Ltd. Soybean lecithin consisting of 90–95% phosphatidylcholine, 1,2-distearoyl-*sn*-glycerol-3-phosphoethanolamine-*N*-[folate(polyethylene glycol)-2000] (DSPE-PEG₂₀₀₀-FA) and 1,2-distearoyl-*sn*-glycerol-3-phosphoethanolamine-*N*-[carboxy(polyethylene glycol)-2000] (DSPE-PEG₂₀₀₀-COOH) were obtained from Shanghai Ponsure Biotech. Co. Ltd. Indocyanine green (ICG) was purchased from Sigma-Aldrich (St. Louis, Mo, USA). Poly(D,L-lactide-co-glycolide) (PLGA, MW: 5000–15 000, lactide : glycolide (50 : 50)) and 4',6-diamidino-2-phenylindole (DAPI) were obtained from Aladdin (Shanghai, China). Trypsin-EDTA solution, phosphate buffer (PBS), fetal bovine serum (FBS), penicillin-streptomycin solution, and RPMI-1640 Media were procured from Corning Inc.

Preparation of FA-PL-MoSe₂

MoSe₂ nanosheets were prepared according to the previously reported methods.^{24,25} In detail, 50 mg MoSe₂ powder was added into 50 mL water, and then the aqueous dispersion was sonicated in an ice-bath by using tip ultrasonic processor (Scientz-IID, 950 W, 25 kHz) with 70% amplitude for 10 h (the sonication was pulsed for 2 s on and 3 s off). The MoSe₂ suspension was centrifuged at 4500 rpm for 20 min to separate the large aggregates. Afterwards, the supernatant was then mixed with 10 mg mL⁻¹ PLGA and sonicated in an ice-bath with 50% amplitude for 3 h to obtain the emulsion. And then, the emulsified mixture was added into 12 mL of deionized water containing soybean phosphatidylcholine and DSPE-PEG₂₀₀₀-FA at

a mass ratio of 2 : 1 under gentle stirring. The FA-PL-MoSe₂ was washed for three times using an Amicon Ultra-4 centrifugal filter (Millipore, Billerica, MA) with a molecular weight cutoff of 100 kDa. As a control, the nanoparticles without FA target molecules were prepared using the same method in which the DSPE-PEG₂₀₀₀-FA was replaced by DSPE-PEG₂₀₀₀-COOH. The purified FA-PL-MoSe₂ was stored at 4 °C before use.

Characterizations

Transmission electron microscope (TEM) images were obtained on a JEOL JEM2011 at 200 kV. Atomic force microscopy (AFM) images were recorded by a Multimode V8 in tapping mode. Dynamic light scattering (DLS) and zeta potential characterization were performed on a Malvern Zetasizer Nano ZS (ZS90). UV-vis absorption spectra ranging from 900 to 400 nm were recorded using a Lambda 750 spectrophotometer (PerkinElmer). The content of Mo in cells and tissue was measured by inductively coupled plasma-atomic emission spectrometry (ICP-AES; Hitachi, P4010). Photothermal effect measurements were performed under irradiation by 808 nm diode laser (Changchun New Industries Optoelectronics Technology Co. Ltd., MDL-III-808R). During NIR irradiation, variation of the temperature was recorded every 30 s using a thermocouple thermometer (Fluke).

Cell culture and cellular uptake

Human lung cancer SPC-A-1 cells were provided by the American Type Culture Collection (ATCC) and cultured in RPMI-1640 media supplemented with 10% FBS and 1% penicillin-streptomycin at 37 °C with 5% CO₂.



For cellular uptake, SPC-A-1 cells (2×10^5 cells per well) were seeded in a 6-well cell culture plate and incubated for 24 h. Afterwards, the media were replaced with fresh RPMI-1640 media containing FA-PL-MoSe₂ and then cultured for an extra 3 h. After discarding the media, cells were gently rinsed with PBS for three times, homogenized, and treated with 1 mL aqua regia solution for 4 h. Mo content internalized by cells was detected by an ICP-AES. In addition, the cells treated with FA-PL-MoSe₂ were collected for Bio-TEM to observe the location of the nanoparticles inner and outer cells. The detailed Bio-TEM was performed according to previous report.³⁰

To further observe the cellular uptake, ICG was used to label the FA-PL-MoSe₂. SPC-A-1 cells adhered to glass slides in 6-well plates and were incubated with free ICG, PL-MoSe₂, FA-PL-MoSe₂ and FA-PL-MoSe₂ + FA blocking at the same concentration of ICG (0.05 mg mL^{-1}) for 3 h, respectively. The cells were then washed with PBS thrice and fixed by 0.2 mL of glutaraldehyde, followed by staining with DAPI for 10 min. The fluorescence images of cells were captured using the laser scanning microscope.

In vitro biocompatibility

In vitro hemolysis assay was conducted according to previous work.³¹ In detail, 0.2 mL separated red blood cells (RBCs) were mixed with 0.8 mL FA-PL-MoSe₂ (in PBS) at predetermined concentrations ($50 \text{ } \mu\text{g mL}^{-1}$, $100 \text{ } \mu\text{g mL}^{-1}$, $150 \text{ } \mu\text{g mL}^{-1}$, $200 \text{ } \mu\text{g mL}^{-1}$ and $250 \text{ } \mu\text{g mL}^{-1}$). RBCs incubated with deionized water or PBS were used as positive or negative control, respectively. After standing incubated at 37°C for 1 h, the above set of suspensions were centrifuged (10 000 rpm, 1 min) and the absorbance of the supernatants at 541 nm was monitored by a UV-vis spectrometer. The hemolytic percentage (HP) was calculated using the following equation.

$$\text{HP}(\%) = \frac{A_t - A_{nc}}{A_{pc} - A_{nc}} \times 100\%$$

where A_t , A_{pc} and A_{nc} are the absorbance of the supernatant at 541 nm of the test sample, positive and negative controls, respectively.

In addition, the cytotoxicity of FA-PL-MoSe₂ was conducted by using a standard CCK-8 assay (Bestbio, China). SPC-A-1 cells (1×10^5 cells per mL, 0.5 mL) were seeded in 96-well plate and cultured for 24 h. After discarding the old media, fresh media containing 0.01, 0.05, 0.1, 0.3 and 0.5 mg mL^{-1} of FA-PL-MoSe₂ were incubated with SPC-A-1 cells for 24 h. PBS was used to mildly wash the cells three times. A 100 μL CCK-8 working solution (10% CCK-8 + 90% RPMI-1640) was then added to each well, followed by incubation at 37°C for 1 h. The absorbance value at 450 nm was detected using a microplate reader (Infinite 200 Pro, Tecan, Austria). Photos of the cells after 24 h treatment with 0.05 and 0.5 mg mL^{-1} of FA-PL-MoSe₂ were collected by an optical microscope.

In vitro photothermal therapy

The *in vitro* photothermal performance of FA-PL-MoSe₂ was tested. In detail, 100 μL FA-PL-MoSe₂ dispersions with different

Mo concentrations were placed in each well of 96-well plate and irradiated under 808 nm laser irradiation for 5 min. The real-time temperature and thermal images of the test samples at different time points (once every 30 seconds) were recorded using the thermocouple thermometer and infrared thermal camera (Fluke TI10, USA), respectively.

For *in vitro* photothermal therapy, SPC-A-1 cells were seeded in 96-well plates (2×10^4 cells per well). After 24 h incubation, the cells were treated with fresh media containing PL-MoSe₂ and FA-PL-MoSe₂ at different Mo concentrations (PBS was used for the control group). After another 12 h, the media were discarded and the free PL-MoSe₂ and FA-PL-MoSe₂ outside the cells were removed *via* PBS washing. After addition of fresh media, the cells were irradiated by an 808 nm laser (1 W cm^{-2} , 5 min). The treated cells were incubated for another 24 h, and cell viability was then measured by a standard CCK-8 assay.

Blood analysis

Five healthy Balb/c nude mice were intravenously injected with 150 μL FA-PL-MoSe₂ at a Mo dose of 15 mg kg^{-1} . Mice treated with saline were used as blank control group. On the day 1, day 7, and day 24 post injection, the mice were sacrificed to collect blood. The whole blood was divided into two parts. The one was centrifuged and the blood supernatant was used to analyze the serum biochemistry parameters including aspartate aminotransferase (AST) and alanine aminotransferase (ALT). The other was used for complete blood counts evaluations including white blood cell (WBC), red blood cells (RBC), hemoglobin (HGB), mean platelet volume (MPV), mean corpuscular hemoglobin (MCH), hematocrit (HCT), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV) and platelet (PLT).

Animal model and *in vivo* biodistribution

Balb/c nude mice (3–5 week old) were used *in vivo* experiments and were purchased from Charles River Laboratories (Beijing, China). 1×10^6 SPC-A-1 cells in 150 μL PBS were subcutaneous injected into the back of Balb/c nude mouse to establish animal tumor model. After tumor volume reached 80 mm³, the mice were used for further *in vivo* experiments. All welfare and experimental procedures in this study were performed in accordance with the policies of National Ministry of Health and approved by the Ethics Committee of Xixiang Medical University.

Systemic biodistribution of FA-PL-MoSe₂ was performed in tumor-bearing mice. The tissues including the tumor, heart, liver, spleen, lung, and kidney were weighed and digested by aqua regia solution overnight at 1 h, 1 day, 7 days, and 24 days post intravenous injection of FA-PL-MoSe₂ (15 mg kg^{-1}). The Mo content in different tissues was then analyzed by an ICP-AES.

In vivo photothermal therapy

Prior to *in vivo* photothermal therapy, tumor-bearing mice treated with saline (blank control), PL-MoSe₂ and FA-PL-MoSe₂. After 24 h intravenous injection, tumor region was irradiated under 808 nm laser irradiation (1 W cm^{-2}) for 5 min, and simultaneously the real-time images were captured by an infrared thermal camera. Moreover, tumor-bearing mice ($n = 5$



per group) were treated with saline, FA-PL-MoSe₂, PL-MoSe₂ + NIR and FA-PL-MoSe₂ + NIR (with 5 mg kg⁻¹ of MoSe₂). After 24 h intravenous injection, tumor region was irradiated under 808 nm laser irradiation (1 W cm⁻²) for 5 min. During the irradiation, the temperature and thermal images of the tumor region at different time points (once every 30 seconds) were recorded using the thermocouple thermometer and infrared thermal camera, respectively. During the treatment, the relative tumor volume (V/V_0 , where V_0 represents tumor volume when the treatment was initiated, *i.e.*, day 0), body weight of each mouse were monitored every four days.

Histology examination

Healthy Balb/c nude mice were intravenously injected with 150 μ L of saline and FA-PL-MoSe₂ (15 mg kg⁻¹) for 1 day or 24 days. And then, mice were sacrificed and the major organs including the heart, liver, spleen, lung, and kidney were collected. The obtained organs were fixed with 4% paraformaldehyde overnight. Afterwards, these organs were dehydrated in 25% sucrose, sectioned into 5 μ m slices and stained with hematoxylin and eosin (H&E). The stained sections were imaged under an inverted phase contrast microscope.

Results and discussion

Preparation and characterization of FA-PL-MoSe₂

Fig. 1 schematically illustrates the preparation of FA-PL-MoSe₂ and the NIR-triggered thermal effect for tumor targeted therapy.

In brief, unstable MoSe₂ nanosheets were prepared from commercial bulk MoSe₂ under ultrasonication, and then stabilized by a PLGA core and PEG-lipid shell, whilst simultaneously being modified by the target molecule FA (Fig. 1a).

The morphology of the as-prepared MoSe₂ nanosheets was observed by TEM to be that of flake-like particles; high-resolution TEM images showed a lattice spacing of 0.21 nm (Fig. 2a and b); DLS analysis showed an average diameter of approximately 20 nm (Fig. 2c). Following PEG-lipid shell formation, the FA-PL-MoSe₂ nanoparticles were almost spherical according to AFM analysis and approximately 200 nm in average diameter as evaluated by DLS analysis (Fig. 2d, e and S1†). The zeta potential of FA-PL-MoSe₂ was determined to be -71 to -18.5 mV (Fig. 2f and S2†).

Prior to preparing the insoluble MoSe₂ nanosheets for biomedical applications, a PEG-lipid shell was assembled around the MoSe₂ nanosheets *via* a self-assembly method to enhance its biocompatibility and physiologic stability. MoSe₂ nanosheets and FA-PL-MoSe₂ were mixed with water, FBS, cell media, PBS, or saline. The average size of the FA-PL-MoSe₂ nanoparticles in these media featured almost no changes over 1 week (Fig. 3a). However, for bare MoSe₂ nanosheets, the nanoparticles inevitably aggregated and precipitated in these media due to the electron screen effect,³² which results in a significant increase of hydrodynamic size (Fig. 3b). These results provide further evidence for the high physiologic stability of FA-PL-MoSe₂, most likely due to the PEG-lipid shell around the MoSe₂ nanosheets.^{33–35}




Fig. 2 (a) The TEM image of MoSe₂ nanosheets and (b) the corresponding high-resolution TEM image. (c) Size distribution of MoSe₂ nanosheets. (d) The typical AFM image of FA-PL-MoSe₂ nanoparticles. The inset was corresponding height profile. The size distribution (e) and zeta potential distribution (f) of FA-PL-MoSe₂ nanoparticles.






Fig. 3 The hydrodynamic particle size change of (a) FA-PL-MoSe₂ and (b) MoSe₂ nanosheets in various media including water, FBS, cell media, PBS and 0.9% NaCl solution over 7 days. Data expressed as the mean \pm S.D. ($n = 4$).

Fig. 4a shows the UV-vis spectra of MoSe₂ nanosheets and FA-PL-MoSe₂. Both particle types had equally strong absorption in the NIR region, indicating that the encapsulation of PEG-lipid did not influence the absorbance intensity of MoSe₂. The temperature change of FA-PL-MoSe₂ aqueous solution at different concentrations (0–150 $\mu\text{g mL}^{-1}$) was recorded under 808 nm irradiation (1 W cm^{-2} , 5 min). Fig. 4b shows the photothermal heating curves, indicating obvious concentration-dependent effects. After 5 min of NIR irradiation, the maximum rising temperature reached approximately 40 °C for the FA-PL-MoSe₂ solution at a concentration of 150

$\mu\text{g mL}^{-1}$; as the control, the temperature of pure water increased by approximately 1 °C under the same conditions. Fig. 4c depicts the photostability of FA-PL-MoSe₂, indicating that it retained its initial excellent photothermal effects without any weakening of temperature elevation after five cycles of irradiation. Furthermore, FA-PL-MoSe₂ presented with similar absorbance spectra before and after five cycles of NIR irradiation (Fig. 4d). These results demonstrate that FA-PL-MoSe₂ has remarkable photostability and an excellent photothermal conversion effect.




Fig. 4 (a) UV-vis absorption spectra of MoSe₂ nanosheets and FA-PL-MoSe₂ (inset: the digital photo of MoSe₂ and FA-PL-MoSe₂ solution). (b) Photothermal heating curves of FA-PL-MoSe₂ solution at different concentrations (0, 10, 20, 50, 100 and 150 $\mu\text{g mL}^{-1}$) under 808 nm laser irradiation (1 W cm^{-2}). (c) Temperature variations of FA-PL-MoSe₂ solution; and (d) UV-vis absorption spectra of FA-PL-MoSe₂ solution before and after the continuous irradiations of 808 nm laser for 5 cycles. Data expressed as the mean \pm S.D. ($n = 4$).



Cellular uptake

After incubation with FA-PL-MoSe₂ for 3 h, the cytoplasm of SPC-A-1 cells showed a large number of FA-PL-MoSe₂ nanoparticles (Fig. 5a), as confirmed from the high-magnification image (Fig. 5b). According to the ICP-AES quantitative analysis, SPC-A-1 cells tended to uptake more FA-PL-MoSe₂ than PL-MoSe₂ (Fig. 5c). To further evaluate the cellular uptake, PL-MoSe₂ and FA-PL-MoSe₂ were labeled by ICG, a NIR fluorescence dye. Fig. 5d shows much stronger ICG fluorescence emitting from inside the cytoplasm in FA-PL-MoSe₂-treated cells than that of PL-MoSe₂- and free ICG-

treated cells. In addition, after FA blocking, SPC-A-1 cells were treated with FA-PL-MoSe₂. There is less ICG fluorescence inside the cytoplasm than FA-PL-MoSe₂-treated cells, which may be due to the blocking of FA receptor on cell by free FA. These data demonstrate that FA facilitated the uptake of FA-PL-MoSe₂ into the cells, likely *via* the receptor-mediated endocytosis pathway.^{36,37}

In vitro biocompatibility

As shown in Fig. 6a, no significant hemolysis phenomenon was detected for FA-PL-MoSe₂-treated RBCs below 250 $\mu\text{g mL}^{-1}$,




Fig. 5 (a) Bio-TEM image of SPC-A-1 cells after incubation with FA-PL-MoSe₂ for 3 h, and (b) the corresponding high-resolution TEM image, yellow arrows indicated the presence of FA-PL-MoSe₂. (c) Quantitative cellular uptake of SPC-A-1 cells towards PL-MoSe₂ and FA-PL-MoSe₂. (d) Confocal fluorescence images of SPC-A-1 cells after incubation with free ICG, PL-MoSe₂, FA-PL-MoSe₂, and FA-PL-MoSe₂ + FA blocking. Red and blue colors represented ICG fluorescence and DAPI stained cell nuclei, respectively. Data expressed as the mean \pm S.D. ($n = 4$).






Fig. 6 (a) Hemolysis ratio of RBCs after 1 hour incubation with FA-PL-MoSe₂ at different concentrations. The inset showed the photograph of RBCs exposed to deionized water, PBS, and FA-PL-MoSe₂ solution with different concentrations followed by centrifugation. (b) Cell viability of SPC-A-1 cells after treatment with PL-MoSe₂ and FA-PL-MoSe₂ at a given Mo concentrations for 24 h. Optical microscope photos of SPC-A-1 cells treated with (c) PBS, (d) 0.05 mg mL⁻¹ and (e) 0.5 mg mL⁻¹ FA-PL-MoSe₂ for 24 h. Data expressed as the mean \pm S.D. ($n = 4$).




Fig. 7 (a) Thermal images of deionized water, PL-MoSe₂ and FA-PL-MoSe₂ (100 µg mL⁻¹), and (b) the corresponding temperature change curves under continuous irradiation with an 808 nm laser irradiation. (c) Cell viability of SPC-A-1 cells treated with 808 nm laser irradiation (5 min, 1 W cm⁻²). Data expressed as the mean \pm S.D. ($n = 4$).



similar to that of the negative PBS-treated group, suggesting an excellent hemocompatibility of FA-PL-MoSe₂.^{38,39} Moreover, the cytotoxicity of the nanoparticles on SPC-A-1 cells was evaluated by the CCK-8 assay. As shown in Fig. 6b, FA-PL-MoSe₂ below 0.5 mg mL⁻¹ exhibited significantly low toxicity to cells, with a higher than 90% cell viability. The cell morphology of SPC-A-1 cells after 24 h of treatment with FA-PL-MoSe₂ (0.05 and 0.5 mg mL⁻¹) exhibited no appreciable change, and was similar to the control group (Fig. 6c–e). These results indicate that the FA-PL-MoSe₂ has a great biocompatibility *in vitro*.

In vitro photothermal therapy

Adherent cells were firstly incubated with PBS, PL-MoSe₂, or FA-PL-MoSe₂ solution (100 µg mL⁻¹ of MoSe₂) for 3 h, respectively. The cells were then treated by 808 nm irradiation (1.0 W cm⁻²) for 5 min. As shown in Fig. 7a, cells treated with FA-PL-MoSe₂ showed the highest temperature increase after 5 min irradiation compared to PL-MoSe₂- and PBS-treated cells, with the highest temperature increase being of 22 °C as detected by a thermometer (Fig. 7b). The cells in these three groups were cultured for a further 21 h, and their viabilities were detected by the CCK-8 assay. As shown in Fig. 7c, the FA-PL-MoSe₂-treated SPC-A-1 cells showed a most significant concentration-dependent cell death due to the FA targeting facilitating the internalization of FA-PL-MoSe₂ and thus the generation of more heat to kill cells.

In vivo biocompatibility

As shown in Fig. 8a, there were no distinct weight changes over 24 days treatment in the control Balb/c mice nor in those treated with FA-PL-MoSe₂, PL-MoSe₂ + NIR, and FA-PL-MoSe₂ + NIR. As illustrated in Fig. 8b–d, complete blood counts (including WBC, RBC, HGB, MPV, MCH, HCT, MCHC, MCV, and PLT), and blood biochemistry (including AST and ALT) in FA-PL-MoSe₂-treated mice over 24 days showed no significant difference compared to the control (saline treated group). Fig. 8e showed no apparent pathological tissue damage or abnormality in major organs (heart, liver, spleen, lung, and kidney) in FA-PL-MoSe₂-treated mice according to H&E staining results. These results demonstrated that FA-PL-MoSe₂ showed low toxicity and excellent *in vivo* biocompatibility.

In vivo photothermal therapy

Tumor-bearing mice were intravenously injected with saline, PL-MoSe₂, and FA-PL-MoSe₂ and, 24 h later, the tumor regions were irradiated by 808 nm laser (1 W cm⁻²) for 5 min. As shown in Fig. 9a and b, NIR irradiation induced the highest temperature increase (by about 20 °C) in FA-PL-MoSe₂-treated tumor regions compared with saline or PL-MoSe₂-treated groups.

The biodistribution of Mo element in various tissues including the heart, liver, spleen, lung, kidney, and tumor at 1 h and 24 h, 7 days and 24 days following an intravenous injection




Fig. 8 (a) Body weight of tumor-bearing mice after various treatments. (b and c) Hematology data and (d) blood biochemistry of mice at days 1, 7 and 24 post treatment with saline (control), and FA-PL-MoSe₂. (e) H&E stained tissue sections of major organs, including the heart, liver, spleen, lung, and kidney from mice treated with saline (control) or FA-PL-MoSe₂ at day 1 and day 24 (magnification: 200×). Data expressed as the mean ± S.D. (n = 5).






Fig. 9 (a) *In vivo* thermal images of mouse after intravenous injection of saline, PL-MoSe₂ and FA-PL-MoSe₂ and 5 min durations NIR irradiation (808 nm, 1 W cm⁻²). (b) The corresponding temperature change curves of tumor regions in mice. (c) Biodistribution of Mo in major tissues, including the heart, liver, spleen, lung, and kidney, and tumor at different time points post treatment with FA-PL-MoSe₂. (d) The tumors growth profile after intravenous injection of saline, PL-MoSe₂ and FA-PL-MoSe₂ with or without 5 min durations NIR irradiation (808 nm, 1 W cm⁻²). Data expressed as the mean ± S.D. (*n* = 5).

of FA-PL-MoSe₂ is shown in Fig. 9c. For the first 24 h post-injection, the majority of the Mo was accumulated in the tumor tissue except for liver and spleen. After 24 h, the Mo level in all tissues decreased with time, while in the tumor, it remained relatively high over seven days, indicating that the nanoparticles could be eliminated from these major organs thus avoiding potential toxic and side effects. These results were likely due to the fact that the PEG-lipid coating can improve the blood circulation duration and effectively decrease the macrophage clearance of nanoparticles by the reticuloendothelial system as well as the FA tumor targeting effect enhancing tumor accumulation.^{40,41}

Fig. 9d shows the *in vivo* photothermal therapy effect of FA-PL-MoSe₂. Due to the excellent targeting and photothermal effects, tumor-bearing mice treated with FA-PL-MoSe₂ combined with 808 nm laser showed significant tumor ablation and growth suppression, and no tumor relapse was observed at 1 month post treatment.

Conclusions

In summary, an excellent photothermal therapy agent based on PEG-lipid coated MoSe₂ nanosheets was successfully synthesized and used for efficient tumor targeted photothermal therapy. The PLGA core and PEG-lipid shell provided the unstable MoSe₂ nanosheets with outstanding physiological stability and photostability, as well as *in vitro* and *in vivo*

biocompatibility. The inner MoSe₂ core can easily absorb and convert NIR laser into hyperthermia, whereas the outer FA coating can facilitate the internalization of nanoparticles into the cells *via* receptor-mediated endocytosis. In addition, *in vitro* and *in vivo* studies showed that, compared with PL-MoSe₂, FA-PL-MoSe₂ coupled with NIR irradiation significantly induced a temperature increase being of about 20 °C and thus had an excellent targeting anticancer efficacy without any toxicity to healthy tissues. Therefore, considering all of the above desirable characteristics, the FA-PL-MoSe₂ nanoparticles will be a promising agent for cancer photothermal therapy.

Conflict of interest

The author reports no conflicts of interest in this work.

Notes and references

- 1 J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman and F. Bray, *Int. J. Cancer*, 2015, **136**, E359–E386.
- 2 J. K. Field, M. Oudkerk, J. H. Pedersen and S. W. Duffy, *Lancet*, 2013, **382**, 732–741.
- 3 S. H. Hyun, J. Y. Choi, K. Kim, J. Kim, Y. M. Shim, S. W. Um, H. Kim, K. H. Lee and B. T. Kim, *Ann. Surg.*, 2013, **257**, 364–370.



- 4 J. M. Lee, G. Y. Jin, S. N. Goldberg, Y. C. Lee, G. H. Chung, Y. M. Han, S. Y. Lee and C. S. Kim, *Radiology*, 2004, **230**, 125–134.
- 5 J. A. Greer, W. F. Pirl, V. A. Jackson, A. Muzikansky, I. T. Lennes, R. S. Heist, E. R. Gallagher and J. S. Temel, *J. Clin. Oncol.*, 2012, **30**, 394–400.
- 6 P. B. Bach, L. D. Cramer, C. B. Begg and J. L. Warren, *N. Engl. J. Med.*, 2000, **342**, 518–519.
- 7 A. M. Roy, C. Bent and T. Fotheringham, *Curr. Probl. Diagn. Radiol.*, 2009, **38**, 44–52.
- 8 K. Hirohashi, T. Anayama, H. Wada, T. Nakajima, T. Kato, S. Keshavjee, K. Orihashi and K. Yasufuku, *J. Bronchology Interv. Pulmonol.*, 2015, **22**, 99–106.
- 9 N. R. Patel, B. S. Pattni, A. H. Abouzeid and V. P. Torchilin, *Adv. Drug Delivery Rev.*, 2013, **65**, 1748–1762.
- 10 F. Zhi, H. Dong, X. Jia, W. Guo, H. Lu, Y. Yang, H. Ju, X. Zhang and Y. Hu, *PLoS One*, 2013, **8**, e60034.
- 11 K. Yang, L. Hu, X. Ma, S. Ye, L. Cheng, X. Shi, C. Li, Y. Li and Z. Liu, *Adv. Mater.*, 2012, **24**, 1868–1872.
- 12 J. Chen, H. Liu, C. Zhao, G. Qin, G. Xi, T. Li, X. Wang and T. Chen, *Biomaterials*, 2014, **35**, 4986–4995.
- 13 C. Li, Z. Liu and P. Yao, *RSC Adv.*, 2016, **6**, 33083–33091.
- 14 Y. W. Chen, Y. L. Su, S. H. Hu and S. Y. Chen, *Adv. Drug Delivery Rev.*, 2016, **105**, 190–204.
- 15 C. Zhang, Y. Y. Fu, X. Zhang, C. Yu, Y. Zhao and S. K. Sun, *Dalton Trans.*, 2015, **44**, 13112–13118.
- 16 H. A. Hoffman, L. Chakrabarti, M. F. Dumont, A. D. Sandler and R. Fernandes, *RSC Adv.*, 2014, **4**, 29729–29734.
- 17 M. Chhowalla, Z. Liu and H. Zhang, *Chem. Soc. Rev.*, 2015, **44**, 2584–2586.
- 18 L. Yang, S. Wang, J. Mao, J. Deng, Q. Gao, Y. Tang and O. G. Schmidt, *Adv. Mater.*, 2013, **25**, 1180–1184.
- 19 R. Deng, H. Yi, F. Fan, L. Fu, Y. Zeng, Y. Wang, Y. Li, Y. Liu, S. Ji and Y. Su, *RSC Adv.*, 2016, **6**, 77083–77092.
- 20 J. Chen, C. Liu, D. Hu, F. Wang, H. Wu, X. Gong, X. Liu, L. Song, Z. Sheng and H. Zheng, *Adv. Funct. Mater.*, 2016, **26**, 8715–8725.
- 21 L. Cheng, J. Liu, X. Gu, H. Gong, X. Shi, T. Liu, C. Wang, X. Wang, G. Liu, H. Xing, W. Bu, B. Sun and Z. Liu, *Adv. Mater.*, 2014, **26**, 1794.
- 22 X. Qian, S. Shen, T. Liu, L. Cheng and Z. Liu, *Nanoscale*, 2015, **7**, 6380–6387.
- 23 W. Z. Teo, E. L. Chng, Z. Sofer and M. Pumera, *Chemistry*, 2014, **20**, 9627–9632.
- 24 L. Yuwen, J. Zhou, Y. Zhang, Q. Zhang, J. Shan, Z. Luo, L. Weng, Z. Teng and L. Wang, *Nanoscale*, 2016, **8**, 2720–2726.
- 25 Z. Lei, W. Zhu, S. Xu, J. Ding, J. Wan and P. Wu, *ACS Appl. Mater. Interfaces*, 2016, **8**, 20900–20908.
- 26 C. Wang, J. Bai, Y. Liu, X. Jia and X. Jiang, *ACS Biomater. Sci. Eng.*, 2016, **2**, 2011–2017.
- 27 P. T. Cagle, Q. J. Zhai, L. Murphy and P. S. Low, *Arch. Pathol. Lab. Med.*, 2013, **137**, 241–244.
- 28 H. Wang, L. Zheng, C. Peng, M. Shen, X. Shi and G. Zhang, *Biomaterials*, 2013, **34**, 470–480.
- 29 M. Salem, Y. Xia, A. Allan, S. Rohani and E. R. Gillies, *RSC Adv.*, 2015, **5**, 37521–37532.
- 30 S. Wang, K. Li, Y. Chen, H. Chen, M. Ma, J. Feng, Q. Zhao and J. Shi, *Biomaterials*, 2015, **39**, 206–217.
- 31 X. Li, Y. Gong, X. Zhou, H. Jin, H. Yan, S. Wang and J. Liu, *Int. J. Nanomed.*, 2016, **11**, 1819–1833.
- 32 L. Chen, W. Feng, X. Zhou, K. Qiu, Y. Miao, Q. Zhang, M. Qin, L. Li, Y. Zhang and C. He, *RSC Adv.*, 2016, **6**, 13040–13049.
- 33 J. M. Chan, L. Zhang, K. P. Yuet, G. Liao, J. W. Rhee, R. Langer and O. C. Farokhzad, *Biomaterials*, 2009, **30**, 1627–1634.
- 34 F. Yu, Y. Li, C. S. Liu, Q. Chen, G. H. Wang, W. Guo, X. E. Wu, D. H. Li, W. D. Wu and X. D. Chen, *Int. J. Pharm.*, 2015, **484**, 181–191.
- 35 L. J. Cruz, M. A. Stammes, I. Que, E. R. van Beek, V. T. Knol-Blanckevoort, T. J. Snoeks, A. Chan, E. L. Kaijzel and C. W. Löwik, *J. Controlled Release*, 2016, **223**, 31–41.
- 36 C. Zheng, M. Zheng, P. Gong, D. Jia, P. Zhang, B. Shi, Z. Sheng, Y. Ma and L. Cai, *Biomaterials*, 2012, **33**, 5603–5609.
- 37 Y. Lu and P. S. Low, *Adv. Drug Delivery Rev.*, 2012, **64**, 342–352.
- 38 H. Wei, L. Han, Y. Tang, J. Ren, Z. Zhao and L. Jia, *J. Mater. Chem. B*, 2015, **3**, 1646–1654.
- 39 C. Shen, X. Liu, B. Fan, C. Shen, X. Liu, B. Fan, P. Lan, F. Zhou, X. Li, H. Wang, X. Xiao, L. Li, S. Zhao, Z. Guo, Z. Pu and Y. Zheng, *RSC Adv.*, 2016, **6**, 86410–86419.
- 40 Q. Xu, L. M. Ensign, N. J. Boylan, A. Schön, X. Gong, J. C. Yang, N. W. Lamb, S. Cai, T. Yu, E. Freire and J. Hanes, *ACS Nano*, 2015, **9**, 9217–9227.
- 41 M. Yang, M. Wada, M. Zhang, K. Kostarelos, R. Yuge, S. Iijima, M. Masuda and M. Yudasaka, *Acta Biomater.*, 2013, **9**, 4744–4753.

